Page 309 - Read Online

Robinson et al. J Cancer Metastasis Treat 2019;5:39 I http://dx.doi.org/10.20517/2394-4722.2019.15 Page 9 of 9

76. Xue Y, Li L, Zhang D, Wu K, Chen Y, et al. Twisted epithelial-to-mesenchymal transition promotes progression of surviving bladder
cancer T24 cells with hTERT-dysfunction. PLoS One 2011;6:e27748.
77. Lagunas AM, Wu J, Crowe DL. Telomere DNA damage signaling regulates cancer stem cell evolution, epithelial mesenchymal transition,
and metastasis. Oncotarget 2017;8:80139-55.
78. El-Badawy A, Ghoneim NI, Nasr MA, Elkhenany H, Ahmed TA, et al. Telomerase reverse transcriptase coordinates with the epithelial-
to-mesenchymal transition through a feedback loop to define properties of breast cancer stem cells. Biol Open 2018;7:bio034181.
79. Nguyen GH, Tang W, Robles AI, Beyer RP, Gray LT, et al. Regulation of gene expression by the BLM helicase correlates with the
presence of G-quadruplex DNA motifs. Proc Natl Acad Sci U S A 2014;111:9905-10.
80. Grudzien P, Lo S, Albain KS, Robinson P, Rajan P, et al. Inhibition of Notch signaling reduces the stem-like population of breast cancer
cells and prevents mammosphere formation. Anticancer Res 2010;30:3853-67.
81. Jafri MA, Ansari SA, Alqahtani MH, Shay JW. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted
therapies. Genome Med 2016;8:69.
82. Hochreiter AE, Xiao H, Goldblatt EM, Gryaznov SM, Miller KD, et al. Telomerase template antagonist GRN163L disrupts telomere
maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res 2006;12:3184-92.
83. Dogan F, Ozates NP, Bagca BG, Abbaszadeh Z, Sogutlu F, et al. Investigation of the effect of telomerase inhibitor BIBR1532 on breast
cancer and breast cancer stem cells. J Cell Biochem 2018.
84. Joseph I, Tressler R, Bassett E, Harley C, Buseman CM, et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and
pancreatic cancer cell lines. Cancer Res 2010;70:9494-504.
85. Koziel JE, Herbert BS. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell
population and self-renewal of HER2+ breast cancer cells. Breast Cancer Res Treat 2015;149:607-18.
86. Cosme-Blanco W, Shen MF, Lazar AJ, Pathak S, Lozano G, et al. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by
initiating p53-dependent cellular senescence. EMBO Rep 2007;8:497-503.
87. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, et al. From latent disseminated cells to overt metastasis: genetic analysis of
systemic breast cancer progression. Proc Natl Acad Sci U S A 2003;100:7737-42.
88. Griffith JK, Bryant JE, Fordyce CA, Gilliland FD, Joste NE, et al. Reduced telomere DNA content is correlated with genomic instability
and metastasis in invasive human breast carcinoma. Breast Cancer Res Treat 1999;54:59-64.
89. Zeng X, Hernandez-Sanchez W, Xu M, Whited TL, Baus D, et al. Administration of a nucleoside analog promotes cancer cell death in a
telomerase-dependent manner. Cell Rep 2018;23:3031-41.
90. Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 2013;39:444-56.
91. Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002;21:674-9.
92. Mender I, Gryaznov S, Dikmen ZG, Wright WE, Shay JW. Induction of telomere dysfunction mediated by the telomerase substrate
precursor 6-thio-2’-deoxyguanosine. Cancer Discov 2015;5:82-95.
93. Zanetti M. A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat Rev Clin Oncol 2017;14:115-28.
94. Sandri S, Bobisse S, Moxley K, Lamolinara A, De Sanctis F, et al. Feasibility of telomerase-specific adoptive t-cell therapy for b-cell
chronic lymphocytic leukemia and solid malignancies. Cancer Res 2016;76:2540-51.
95. Flynn RL, Cox KE, Jeitany M, Wakimoto H, Bryll AR, et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to
ATR inhibitors. Science 2015;347:273-7.
96. Drosopoulos WC, Kosiyatrakul ST, Schildkraut CL. BLM helicase facilitates telomere replication during leading strand synthesis of
telomeres. J Cell Biol 2015;210:191-208.
97. Pan X, Drosopoulos WC, Sethi L, Madireddy A, Schildkraut CL, et al. FANCM, BRCA1, and BLM cooperatively resolve the replication
stress at the ALT telomeres. Proc Natl Acad Sci U S A 2017;114:E5940-E9.
98. Nguyen GH, Dexheimer TS, Rosenthal AS, Chu WK, Singh DK, et al. A small molecule inhibitor of the BLM helicase modulates
chromosome stability in human cells. Chem Biol 2013;20:55-62.
99. Temime-Smaali N, Guittat L, Wenner T, Bayart E, Douarre C, et al. Topoisomerase IIIalpha is required for normal proliferation and
telomere stability in alternative lengthening of telomeres. EMBO J 2008;27:1513-24.
100. Tsai HJ, Huang WH, Li TK, Tsai YL, Wu KJ, et al. Involvement of topoisomerase III in telomere-telomere recombination. J Biol Chem
2006;281:13717-23.
101. Ward RJ, Autexier C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic
treatment. Mol Pharmacol 2005;68:779-86.